Form 8-K

8-K — CareDx, Inc.

Accession: 0001217234-26-000045

Filed: 2026-07-30

Period: 2026-07-30

CIK: 0001217234

SIC: 8071 (SERVICES-MEDICAL LABORATORIES)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — cdna-20260730.htm (Primary)

EX-99.1 (cdna-20260730_earningsrele.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: cdna-20260730.htm · Sequence: 1

cdna-20260730

0001217234FALSE00012172342026-07-302026-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 30, 2026

CAREDX, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-36536

94-3316839

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

8000 Marina Boulevard

Brisbane, California 94005

(Address of Principal Executive Offices) (Zip Code)

(415) 287-2300

Registrant’s telephone number, including area code

N/A

(Former Name, or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)

(Trading Symbol)

(Name of exchange on which registered)

Common Stock, $0.001 Par Value

CDNA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On July 30, 2026, CareDx, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is intended to be furnished under Item 2.02 and Item 9.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 Regulation FD Disclosure.

The Company is posting an updated corporate presentation (the “Corporate Presentation”) on its website. The Corporate Presentation is current as of June 30, 2026, and the Company disclaims any obligation to update this material in the future.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release issued by CareDx, Inc., dated June 30, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CAREDX, INC.

Date: June 30, 2026

By:

/s/ JOHN HANNA

John W. Hanna

President, Chief Executive Officer and Director

EX-99.1

Filename: cdna-20260730_earningsrele.htm · Sequence: 2

Document

Exhibit 99.1

CareDx Announces Second Quarter 2026 Financial Results

Second Quarter Revenue Growth of 52% to $132 Million

Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million

BRISBANE, Calif. — (BUSINESS WIRE) — CareDx, Inc. (Nasdaq: CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Highlights

• Revenue of $132 million, an increase of 52% year-over-year

• Testing Services revenue of $100 million, an increase of 61% year-over-year, and Testing Services volume of approximately 58,000, an increase of 17% year-over-year

• Patient and Digital Solutions revenue of $19 million and Lab Product revenue of $13 million, representing year-over-year growth of 50% and 8%, respectively

• Average revenue per test of approximately $1,720, including $16 million in prior period revenue

• GAAP net income of $111 million, compared to GAAP net loss of $9 million for the second quarter of 2025

• Closed the sale of the Lab Products business on June 30, recognizing a $113 million gain on sale included in GAAP operating income and excluded from non-GAAP operating income

• Adjusted EBITDA of $25 million, compared to $5 million for the second quarter of 2025

• Cash flow from operations of $31 million

Recent Business Highlights

• Completed the divestiture of the Lab Products business to Eurobio Scientific and closed the acquisition of Naveris, strengthening CareDx’s position as a precision medicine diagnostics company focused on transplant, specialty oncology, and cell therapy

• CMS finalized Medicare coverage policy for AlloSure® and AlloMap®, supporting continued patient access to molecular testing in transplant care

• Advanced the AlloHeme® pipeline program with submission of a clinical validation manuscript and continued progress toward CLIA readiness

• Published new HistoMap® Kidney data in Transplantation, expanding the evidence base for this pipeline program and supporting the potential role of molecular assessment to complement conventional histopathology in kidney transplant biopsies

• Presented new data at the American Head and Neck Society (AHNS) Annual Meeting, expanding the clinical evidence supporting NavDx® and its role in informing patient management decisions

• Presented new data at the American Transplant Congress (ATC), expanding the clinical evidence supporting AlloSure®, including data supporting its role in identifying patients at risk of graft loss and in assessing response to therapy

• Published new KOAR data in the Journal of the American Society of Nephrology supporting the role of AlloSure® Kidney in longitudinal risk stratification and clinical decision-making for kidney transplant recipients

"We have transformed CareDx into a differentiated precision molecular diagnostics company with a unique set of core competencies that position us for continued profitable growth," said John Hanna, President and Chief

Executive Officer of CareDx. "Our performance reflects that our strategy is working, and we look forward to building on our momentum as we integrate NavDx and launch into cell therapy.”

Second Quarter 2026 Financial Results

Total revenue was $132 million, compared to $87 million in the second quarter of 2025, an increase of 52% year-over-year, driven primarily by higher Testing Services revenue and continued expansion of Patient and Digital Solutions revenue. Revenue growth reflected continued demand across transplant programs, favorable reimbursement dynamics, and increases in testing activity across both surveillance and for-cause settings.

Testing services revenue was $100 million, compared to $62 million in the second quarter of 2025, an increase of 61% year over year, and testing services volume was approximately 58,000, an increase of 17% year over year. Excluding revenue recognized for tests performed in prior periods, testing services revenue increased approximately 28% year-over-year. Testing services revenue reflected ongoing adoption of molecular surveillance testing across transplant programs.

Patient and Digital Solutions revenue was $19 million, compared to $13 million in the second quarter of 2025, an increase of 50% year-over-year, driven by continued growth in CareDx Pharmacy services and adoption of patient support and digital solutions across transplant monitoring.

Lab Product revenue was $13 million, compared to $12 million in the second quarter of 2025, an increase of 8% year-over-year. The quarter reflects a full period of Lab Products results, as the divestiture to Eurobio Scientific closed on June 30, 2026. Future periods will no longer include Lab Products segment results.

GAAP net income was $111 million, compared to GAAP net loss of $9 million in the second quarter of 2025. Basic and diluted GAAP net income per share was $2.15 and $2.07, respectively, compared to basic and diluted GAAP net loss per share of $0.16 in the second quarter of 2025. These results reflect strong operational performance, as well as the sale of our Lab Products business, which closed on June 30. The transaction resulted in a $113 million gain that is included in GAAP operating income and excluded from non-GAAP operating income.

Non-GAAP net income was $20 million, compared to $6 million in the second quarter of 2025. Diluted non-GAAP net income per share was $0.37 compared to $0.10 in the second quarter of 2025.

Adjusted EBITDA was $25 million, compared to $5 million in the second quarter of 2025, driven by strong Testing Services revenue growth, improved gross profit, and continued focus on operational efficiency and cost discipline.

2026 Guidance

For the full year 2026, CareDx now expects revenue to be in the range of $490 million to $500 million, compared to the $447 million to $465 million range that was previously disclosed. The Company now expects full year 2026 adjusted EBITDA to be in the range of $66 million to $78 million, compared to its previously disclosed range of $43 million to $57 million.

About CareDx

CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, please visit www.caredx.com.

Forward Looking Statements

This press release includes forward-looking statements, including expectations regarding the achievement of CareDx’s financial and operational goals and its expectations and prospects for 2026. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond CareDx’s control, that could cause the actual results to differ materially from those projected, including general economic and market factors, and global economic and marketplace uncertainties, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed by CareDx with the SEC on February 25, 2026, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or

implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Non-GAAP Financial Measures

CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) and also on a non-GAAP basis, including non-GAAP cost of testing services, non-GAAP cost of product, non-GAAP cost of patient and digital solutions, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other income, net, non-GAAP income tax expense, non-GAAP gross profit, non-GAAP gross margin (%), non-GAAP operating expenses, non-GAAP net income, non-GAAP basic and diluted net income per share, adjusted EBITDA and adjusted EBITDA margin. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.

We define non-GAAP net income and per share results as the GAAP net income (loss) and per share results excluding the impacts of stock-based compensation expense; acquisition-related amortization of purchased intangible assets and related tax effects; changes in estimated fair value of contingent consideration; litigation settlement expense; business development and portfolio optimization expense; gain on sale of lab product business; and certain other charges presented in the reconciliation in this release. We define adjusted EBITDA as non-GAAP net income before interest income, income tax expense, depreciation expense and other (income) expense, net. We define non-GAAP gross profit and non-GAAP gross margin as GAAP gross profit and GAAP gross margin excluding the impacts of stock-based compensation expense, and acquisition-related amortization of purchased intangible assets included in cost of sales. Non-GAAP gross margin is calculated as non-GAAP gross profit divided by total revenue. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenue. Corporate free cash flow is defined as Cash from Operations less Capital Expenditures.

We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods where certain items may vary independent of business performance. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx’s operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables. A reconciliation of the forecasted range for adjusted EBITDA for 2026 is not included in this release due to the number of variables in the projected range and because we are currently unable to quantify accurately certain amounts that would be required to be included in the U.S. GAAP measure or the individual adjustments for such reconciliation.

CareDx, Inc.

Media Relations

Natasha Moshirian Wagner

nwagner@CareDx.com

Investor Relations

Nina Deka

investor@CareDx.com

CareDx, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended June 30,

2026 2025

Revenue:

Testing services revenue $ 99,927 $ 62,033

Product revenue 12,791 11,833

Patient and digital solutions revenue

19,230 12,813

Total revenue 131,948 86,679

Operating expenses:

Cost of testing services 15,918 15,406

Cost of product 4,342 4,981

Cost of patient and digital solutions 14,706 8,271

Research and development 22,376 16,830

Sales and marketing 33,441 24,279

General and administrative 40,908 27,683

Gain on sale of lab products business (112,966) —

Litigation settlement expense

— 350

Total operating expenses 18,725 97,800

Income (loss) from operations 113,223 (11,121)

Other income:

Interest income, net 1,735 2,364

Other (expense) income, net (440) 72

Total other income 1,295 2,436

Income (loss) before income taxes 114,518 (8,685)

Income tax (expense) benefit (3,882) 117

Net income (loss) $ 110,636 $ (8,568)

Net income (loss) per share (Note 3):

Basic $ 2.15 $ (0.16)

Diluted $ 2.07 $ (0.16)

Weighted-average shares used to compute net income (loss) per share:

Basic 51,469,375 54,304,754

Diluted 53,422,523 54,304,754

CareDx, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands)

As of

June 30, 2026 December 31, 2025

Assets

Current assets:

Cash and cash equivalents $ 373,636 $ 65,429

Marketable securities — 111,779

Accounts receivable 34,377 42,628

Inventory 6,982 26,705

Prepaid and other current assets 14,228 10,591

Total current assets 429,223 257,132

Property and equipment, net 26,838 32,971

Operating lease right-of-use assets 16,203 22,760

Marketable securities, non-current — 24,165

Intangible assets, net 18,556 31,960

Goodwill 35,968 40,336

Restricted cash 521 551

Other assets 5,679 3,353

Total assets $ 532,988 $ 413,228

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable $ 9,493 $ 9,988

Accrued compensation 34,571 38,107

Accrued and other liabilities 49,634 41,754

Total current liabilities 93,698 89,849

Deferred tax liability 86 181

Operating lease liabilities, less current portion 13,200 19,679

Other liabilities 406 418

Total liabilities 107,390 110,127

Commitments and contingencies

Stockholders’ equity:

Common stock

51 50

Additional paid-in capital 930,993 927,457

Accumulated other comprehensive loss — (5,515)

Accumulated deficit (505,446) (618,891)

Total stockholders’ equity 425,598 303,101

Total liabilities and stockholders’ equity $ 532,988 $ 413,228

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

(In thousands)

Three Months Ended June 30,

2026 2025

Cost of testing services reconciliation:

GAAP cost of testing services $ 15,918 $ 15,406

Stock-based compensation expense (200) (329)

Acquisition related-amortization of purchased intangibles (202) (346)

Non-GAAP cost of testing services $ 15,516 $ 14,731

Cost of product reconciliation:

GAAP cost of product $ 4,342 $ 4,981

Stock-based compensation expense (15) (108)

Acquisition related-amortization of purchased intangibles — (442)

Business development and portfolio optimization expense* (311) —

Restructuring costs — (164)

Non-GAAP cost of product $ 4,016 $ 4,267

Cost of patient and digital solutions reconciliation:

GAAP cost of patient and digital solutions $ 14,706 $ 8,271

Stock-based compensation expense (106) (189)

Acquisition related-amortization of purchased intangibles (153) (153)

Restructuring costs — (174)

Non-GAAP cost of patient and digital solutions $ 14,447 $ 7,755

Research and development expenses reconciliation:

GAAP research and development expenses $ 22,376 $ 16,830

Stock-based compensation expense (1,121) (1,407)

Business development and portfolio optimization expense* (504) —

Non-GAAP research and development expenses $ 20,751 $ 15,423

Sales and marketing expenses reconciliation:

GAAP sales and marketing expenses $ 33,441 $ 24,279

Stock-based compensation expense (1,566) (2,146)

Acquisition related-amortization of purchased intangibles (174) (648)

Business development and portfolio optimization expense* (1,262) —

Restructuring costs — 12

Non-GAAP sales and marketing expenses $ 30,439 $ 21,497

General and administrative expenses reconciliation:

GAAP general and administrative expenses $ (72,058) $ 28,033

Business development and portfolio optimization expense*

(9,001) —

Stock-based compensation expense (7,646) (5,245)

Change in estimated fair value of contingent consideration — (501)

Litigation settlement expense — (350)

Acquisition related fees and expenses — (204)

Gain on sale of lab products business 112,966 —

Restructuring costs — (34)

Transformational initiative costs — (1,871)

Non-GAAP general and administrative expenses $ 24,261 $ 19,828

Total other income reconciliation:

GAAP other income $ 1,295 $ 2,436

Non-GAAP other income $ 1,295 $ 2,436

Income tax (expense) benefit reconciliation:

GAAP income tax (expense) benefit $ (3,882) $ 117

Tax effect related to amortization of purchased intangibles 54 (109)

Non-GAAP income tax (expense) benefit $ (3,828) $ 8

* Business development and portfolio optimization expense primarily includes legal, consulting, financial advisory, due diligence, and other transaction-related costs incurred in connection with business development activities, including the sale of our lab products business and acquisition of Naveris, Inc.

CareDx, Inc.

GAAP and Non-GAAP Operating Expenses

(Unaudited)

(In thousands)

Three Months Ended June 30,

2026 2025

GAAP operating expenses:

Research and development $ 22,376 $ 16,830

Sales and marketing 33,441 24,279

General and administrative (72,058) 28,033

Total GAAP operating expenses $ (16,241) $ 69,142

Non-GAAP operating expenses:

Research and development $ 20,751 $ 15,423

Sales and marketing 30,439 21,497

General and administrative 24,261 19,828

Total Non-GAAP operating expenses $ 75,451 $ 56,748

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin

(Unaudited)

(In thousands, except percentages)

Three Months Ended June 30,

2026 2025

GAAP total revenue

$ 131,948 $ 86,679

GAAP cost of sales 34,966 28,658

GAAP gross profit 96,982 58,021

GAAP gross margin %

74 % 67 %

Stock-based compensation expense 321 626

Restructuring costs

— 338

Business development and portfolio optimization expense* 311 —

Acquisition related-amortization of purchased intangibles 355 941

Non-GAAP gross profit $ 97,969 $ 59,926

Non-GAAP gross margin % 74 % 69 %

CareDx, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited)

(In thousands, except share and per share data)

Three Months Ended June 30,

2026 2025

GAAP net income (loss) $ 110,636 $ (8,568)

Gain on sale of lab products business (112,966) —

Stock-based compensation expense 10,654 9,424

Business development and portfolio optimization expense*

11,078 —

Acquisition related-amortization of purchased intangibles 529 1,589

Acquisition related fees and expenses — 204

Change in estimated fair value of contingent consideration — 501

Tax effect related to amortization of purchased intangibles 54 (109)

Transformational initiative costs — 1,871

Restructuring costs — 360

Litigation settlement expense — 350

Non-GAAP net income $ 19,985 $ 5,622

GAAP basic net income (loss) per share $ 2.15 $ (0.16)

GAAP diluted net income (loss) per share $ 2.07 $ (0.16)

Non-GAAP basic net income per share $ 0.39 $ 0.10

Non-GAAP diluted net income per share $ 0.37 $ 0.10

Shares used in computing non-GAAP basic net income per share 51,469,375 54,304,754

Shares used in computing non-GAAP diluted net income per share 53,422,523 56,385,713

CareDx, Inc.

Reconciliation of Non-GAAP to Adjusted EBITDA

(Unaudited)

(In thousands)

Three Months Ended June 30,

2026

2025

GAAP net income (loss) $ 110,636 $ (8,568)

Gain on sale of lab products business (112,966) —

Stock-based compensation expense 10,654 9,424

Business development and portfolio optimization expense*

11,078 —

Acquisition related-amortization of purchased intangibles 529 1,589

Acquisition related fees and expenses — 204

Change in estimated fair value of contingent consideration — 501

Tax effect related to amortization of purchased intangibles 54 (109)

Transformational initiative costs — 1,871

Restructuring costs — 360

Litigation settlement expense — 350

Non-GAAP net income 19,985 5,622

Interest income (1,735) (2,364)

Income tax expense (income) 3,828 (8)

Depreciation expense 2,286 2,132

Other expense (income), net 440 (72)

Adjusted EBITDA $ 24,804 $ 5,310

CareDx, Inc.

Reconciliation of GAAP Net Income Margin to Adjusted EBITDA Margin

(Unaudited)

(In thousands)

Three Months Ended June 30,

2026

2025

GAAP net income (loss) $ 110,636 $ (8,568)

GAAP net income margin 84 % (10) %

Gain on sale of lab products business (112,966) —

Stock-based compensation expense 10,654 9,424

Business development and portfolio optimization expense*

11,078 —

Acquisition related-amortization of purchased intangibles 529 1,589

Acquisition related fees and expenses — 204

Change in estimated fair value of contingent consideration — 501

Tax effect related to amortization of purchased intangibles 54 (109)

Transformational initiative costs — 1,871

Restructuring costs — 360

Litigation settlement expense — 350

Non-GAAP net income 19,985 5,622

Interest income (1,735) (2,364)

Income tax expense (income) 3,828 (8)

Depreciation expense 2,286 2,132

Other expense (income), net 440 (72)

Adjusted EBITDA $ 24,804 $ 5,310

Revenue $ 131,948 $ 86,679

Adjusted EBITDA margin 19 % 6 %

CareDx, Inc.

Net Cash Provided by Operating Activities Reconciliation to Free Cash Flow

(Unaudited)

(In thousands)

Three Months Ended June 30,

2026

2025

Net cash provided by operating activities (GAAP)

$ 30,606 $ 9,898

Less: item not included in free cash flows

Capital expenditures (GAAP)

$ (1,858) $ (1,007)

Free cash flow (non-GAAP) $ 28,748 $ 8,891

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover Page

Jul. 30, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Jul. 30, 2026

Entity Registrant Name

CAREDX, INC.

Entity Incorporation, State or Country Code

Entity File Number

001-36536

Entity Tax Identification Number

94-3316839

Entity Address, Address Line One

8000 Marina Boulevard

Entity Address, City or Town

Brisbane

Entity Address, State or Province

Entity Address, Postal Zip Code

94005

City Area Code

415

Local Phone Number

287-2300

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 Par Value

Trading Symbol

CDNA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Central Index Key

0001217234

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration